In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lion buys rights to BMS's OTC analgesics for Y30.4bn

Executive Summary

Japanese consumer care firm Lion has paid Y30.4bn ($250mm) to acquire rights to Bristol-Myers Squibb's Bufferin and Excedrin nonprescription pain relievers in Japan, Korea, Thailand, Malaysia, Indonesia, Hong Kong, Macau, Singapore, Brunei, Cambodia, Vietnam, India, Bangladesh, Pakistan, Sri Lanka, Australia, New Zealand, and Fiji.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies